Cipralex significantly reduces the risk of relapse in patients with OCD

Kaplan-Meier survival analysis of relapse(ref 1.)

Cipralex has a statistically significantly superior effect relative to placebo on the time to relapse of OCD

Patients in remission (ref 1)

During Weeks 20 to 40, a significantly higher percentage of Cipralex(escitalopram)-treated patients responded to treatment compared with placebo-treated patients:

Week 20, p<0.01

Weeks 22–40, p<0.001

References

1. N. Fineberg et al. European Neuropsychopharmacology 2007, in press